



ASX ANNOUNCEMENT

Lumos strengthens U.S. strategy with AcuityMD strategic collaboration to track and optimize FebriDx reimbursement outcomes

MELBOURNE, Australia (20 November 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) is pleased to announce that it has entered into a strategic collaboration with AcuityMD to support the U.S. commercialization of its flagship FebriDx® test through enhanced visibility into reimbursement performance under the established Proprietary Laboratory Analyses (PLA) Code #0442U, through its AI platform.

Understanding U.S. reimbursement complexity

The U.S. healthcare reimbursement environment differs significantly from publicly funded systems. While a test may obtain a Current Procedural Terminology (CPT) or PLA code, like FebriDx® at US\$41.38, this code represents a reference amount and not guaranteed payment per test. Payments ultimately depend on each payer’s reimbursement policy, contracted rates, and the provider’s billing eligibility. Certain private insurers may reimburse above or below that reference amount, or not at all, depending on medical policy coverage and claims validation. Establishing dependable reimbursement where providers are consistently and efficiently paid for performing a test is essential to drive adoption, repeat usage, and sustainable revenue growth. Many diagnostic technologies with high published reimbursement rates have struggled to achieve commercial uptake due to underappreciating these system dynamics.

Tracking real-world reimbursement activity

Through its AI-enabled platform and partnering directly with the Centers for Medicare & Medicaid Services (CMS) and medical claims aggregators, AcuityMD harmonizes, cleans, and surfaces insights from over 330 million patients. Working in parallel with Lumos’ U.S. commercial collaborator, PRO-spectus (ASX: 14 August 2025), these insights will verify whether the ongoing field efforts are achieving the reimbursement outcomes required for broad utilization and repeat business. Securing inclusion of the PLA rate in private payer policies represents a key enabler for sustainable scaling of FebriDx® in the U.S. primary care and urgent care markets.

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections in around 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

Commenting on the announcement, Mike Monovoukas, CEO and co-founder of AcuityMD, said: *“We’re delighted to partner with Lumos Diagnostics to expand access to FebriDx® in the U.S. This partnership supports our mission to accelerate the adoption of cutting-edge medical technology. With AcuityMD’s insights, Lumos can focus their efforts where FebriDx® will have the greatest impact on patients.”*

Doug Ward, CEO of Lumos Diagnostics, said: *“Our partnership with AcuityMD represents another important step in strengthening our commercial capabilities in the US. Access to AcuityMD’s data-driven insights will allow us to better understand and respond to reimbursement trends for FebriDx®, supporting our broader goal of driving adoption across healthcare settings. Alongside PRO-spectus, this collaboration will position Lumos to execute a more focused and effective commercial rollout strategy in the months and years ahead.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About AcuityMD

AcuityMD is the AI platform for MedTech, used by more than 400 companies, including eight of the top 10. Commercial leaders rely on AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to [Forbes’ 2025 “Next Billion-Dollar Startups” list](#) – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a \$1 billion valuation. For more information visit AcuityMD.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598